Cargando…

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly

After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulahannan, Danny, Wagg, Adrian
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685240/
https://www.ncbi.nlm.nih.gov/pubmed/19503781
_version_ 1782167306306060288
author Ulahannan, Danny
Wagg, Adrian
author_facet Ulahannan, Danny
Wagg, Adrian
author_sort Ulahannan, Danny
collection PubMed
description After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerability of this group of drugs when used in older people. This article reviews the pathophysiology of the condition, its effect on the elderly and the evidence for the use of extended release tolterodine in the elderly using data from placebo and active drug controlled studies.
format Text
id pubmed-2685240
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26852402009-06-05 The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly Ulahannan, Danny Wagg, Adrian Clin Interv Aging Review After lifestyle and behavioral measures to control overactive bladder, the mainstay of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predominantly affects older people, who experience the most severe disease, and are also at a greater risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available on the efficacy and tolerability of this group of drugs when used in older people. This article reviews the pathophysiology of the condition, its effect on the elderly and the evidence for the use of extended release tolterodine in the elderly using data from placebo and active drug controlled studies. Dove Medical Press 2009 2009-05-14 /pmc/articles/PMC2685240/ /pubmed/19503781 Text en © 2009 Ulahannan and Wagg, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Ulahannan, Danny
Wagg, Adrian
The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
title The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
title_full The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
title_fullStr The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
title_full_unstemmed The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
title_short The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
title_sort safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685240/
https://www.ncbi.nlm.nih.gov/pubmed/19503781
work_keys_str_mv AT ulahannandanny thesafetyandefficacyoftolterodineextendedreleaseinthetreatmentofoveractivebladderintheelderly
AT waggadrian thesafetyandefficacyoftolterodineextendedreleaseinthetreatmentofoveractivebladderintheelderly
AT ulahannandanny safetyandefficacyoftolterodineextendedreleaseinthetreatmentofoveractivebladderintheelderly
AT waggadrian safetyandefficacyoftolterodineextendedreleaseinthetreatmentofoveractivebladderintheelderly